Search results
Results from the WOW.Com Content Network
Lipodystrophy can appear as a lump or small dent in the skin that forms when a person performs injections repeatedly in the same spot. These types of lipodystrophies are harmless and can be avoided by changing (rotating) the locations of injections. For those with diabetes, using purified insulins and new needles with each injection may also help.
Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes, from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis. In the latter case, an injection may produce a small ...
They are harmless. See also: Lipoatrophy; injection site rotation. Insulin-induced hypertrophy Small lumps that form under the skin when a person keeps injecting a needle in the same spot. See also: Lipodystrophy; injection site rotation. Insulin pen An insulin injection device the size of a pen that includes a needle attached to a vial of insulin.
Localized lipodystrophy. Specialty. Dermatology. Localized lipodystrophy is a skin condition characterized by the loss of subcutaneous fat localized to sites of insulin injection. [1]: 497.
Lipohypertrophy[1] is a lump under the skin caused by accumulation of extra fat at the site of many subcutaneous injections of insulin. It may be unsightly, mildly painful, and may change the timing or completeness of insulin action. It is a common, minor, chronic complication of diabetes mellitus. Typical injection site hypertrophy is several ...
Lipohypertrophy may be caused by insulin therapy. Repeated insulin injections at the same site, or near to, causes an accumulation of extra subcutaneous fat and may present as a large lump under the skin. It may be unsightly, mildly painful, and may change the timing or completeness of insulin action.
Lipoatrophic diabetes. Specialty. Endocrinology. Lipoatrophic diabetes is a type of diabetes mellitus presenting with severe lipodystrophy in addition to the traditional signs of diabetes.
In many people, both a rapid- or short-acting insulin product as well as an intermediate- or long-acting product are used to decrease the amount of injections per day. In some, insulin injections may be combined with other injection therapy such as GLP-1 receptor agonists. Cleansing of the injection site and injection technique are required to ...